Completed OBSERVATIONAL NCT02069639

TARC After alloSCT in Hodgkin's Lymphoma (TARC)

Serum Thymus and Activation-regulated Chemokine (TARC) Level Monitoring May Predict Disease Relapse Detected by PET Scan After Reduced Intensity Allogeneic Stem Cell Transplantation in Hodgkin's Lymphoma Patients

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Conditions Hodgkin's Lymphoma Patients Who Underwent an Allogeneic Stem Cell Transplantation

Interventions no treatment

Updated 6 times since 2017 Last updated: Feb 20, 2014 Started: Nov 30, 2013 Primary completion: Jan 31, 2014 Completion: Jan 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02069639, this observational or N/A phase trial focuses on Hodgkin's Lymphoma Patients Who Underwent an Allogeneic Stem Cell Transplantation and remains completed. Sponsored by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, it has been updated 6 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Data source: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Milan, Italy